When a Promising Pain Drug Falters: Revisiting the Regulatory Rejection of an NGF Inhibitor
Tanezumab was positioned as a landmark non-opioid therapy for chronic osteoarthritis pain, yet it never reached American patients. We examine the clinical evidence, the joint-safety signals, and the regulatory reasoning behind two complete response letters.